📰 Morphic Therapeutic News
Page 2 - Morphic Therapeutic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Morphic Therapeutic. Real-time updates on events, politics, business and more.
September 25, 2023
Since Friday, Morphic Therapeutic MORF shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new…
September 22, 2023
-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures- ...
August 3, 2023
-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial...
May 3, 2023
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral...
May 1, 2023
Operator: Good day, and welcome to the Alexandria Real Estate Equities First Quarter 2023 Conference Call. All participants will be in listen-only mode.
April 26, 2023
Health news and commentary from around the Web gathered by <em>MedPage Today</em> staff
April 25, 2023
-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements...
April 25, 2023
The ulcerative colitis R&D space is heating up once again, as Morphic Therapeutic touted positive mid-stage data for its oral med. At week 12, the small…
October 11, 2022
Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced that